Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer

Kumiko Karasawa, H. Shinoda, Kuniaki Katsui, K. Seki, M. Kohno, N. Hanyu, S. Nasu, H. Muramatsu, K. Maebayashi, N. Mitsuhashi, T. Yoshihara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: This study was designed to evaluate the concomitant use of docetaxel and carboplatin for radiosensitization in head and neck cancer. Materials and Methods: One dose of docetaxel at 10 mg/m2 and five doses of carboplatin at AUC of 0.4 per week were administered to patients during the first two weeks of radiotherapy. Sixteen patients were treated with this regimen. Radiotherapy was given to a total dose of 64.8 to 82.0 Gy. Altered fractionation radiotherapy was performed in 12 patients with untreated advanced tumors. Results: The complete response (CR) rate was 81%, with a partial response (PR) rate of 19%. Toxicities included grade 3 mucositis in 69% of patients and grade 2 dermatitis in 56% of patients. Conclusion: This schedule of docetaxel and carboplatin combined with radiotherapy may become a useful approach for the management of head and neck cancer with proper management of mucositis.

Original languageEnglish
Pages (from-to)3785-3788
Number of pages4
JournalAnticancer Research
Volume22
Issue number6 B
Publication statusPublished - Nov 2002
Externally publishedYes

Fingerprint

docetaxel
Carboplatin
Head and Neck Neoplasms
Radiotherapy
Mucositis
Dermatitis
Area Under Curve
Appointments and Schedules

Keywords

  • Chemoradiotherapy
  • Concurrrent chemotherapy
  • Docetaxel
  • Head and neck cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Karasawa, K., Shinoda, H., Katsui, K., Seki, K., Kohno, M., Hanyu, N., ... Yoshihara, T. (2002). Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Research, 22(6 B), 3785-3788.

Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. / Karasawa, Kumiko; Shinoda, H.; Katsui, Kuniaki; Seki, K.; Kohno, M.; Hanyu, N.; Nasu, S.; Muramatsu, H.; Maebayashi, K.; Mitsuhashi, N.; Yoshihara, T.

In: Anticancer Research, Vol. 22, No. 6 B, 11.2002, p. 3785-3788.

Research output: Contribution to journalArticle

Karasawa, K, Shinoda, H, Katsui, K, Seki, K, Kohno, M, Hanyu, N, Nasu, S, Muramatsu, H, Maebayashi, K, Mitsuhashi, N & Yoshihara, T 2002, 'Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer', Anticancer Research, vol. 22, no. 6 B, pp. 3785-3788.
Karasawa K, Shinoda H, Katsui K, Seki K, Kohno M, Hanyu N et al. Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Research. 2002 Nov;22(6 B):3785-3788.
Karasawa, Kumiko ; Shinoda, H. ; Katsui, Kuniaki ; Seki, K. ; Kohno, M. ; Hanyu, N. ; Nasu, S. ; Muramatsu, H. ; Maebayashi, K. ; Mitsuhashi, N. ; Yoshihara, T. / Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. In: Anticancer Research. 2002 ; Vol. 22, No. 6 B. pp. 3785-3788.
@article{de9d5107707e40abbf85b06a3284862b,
title = "Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer",
abstract = "Background: This study was designed to evaluate the concomitant use of docetaxel and carboplatin for radiosensitization in head and neck cancer. Materials and Methods: One dose of docetaxel at 10 mg/m2 and five doses of carboplatin at AUC of 0.4 per week were administered to patients during the first two weeks of radiotherapy. Sixteen patients were treated with this regimen. Radiotherapy was given to a total dose of 64.8 to 82.0 Gy. Altered fractionation radiotherapy was performed in 12 patients with untreated advanced tumors. Results: The complete response (CR) rate was 81{\%}, with a partial response (PR) rate of 19{\%}. Toxicities included grade 3 mucositis in 69{\%} of patients and grade 2 dermatitis in 56{\%} of patients. Conclusion: This schedule of docetaxel and carboplatin combined with radiotherapy may become a useful approach for the management of head and neck cancer with proper management of mucositis.",
keywords = "Chemoradiotherapy, Concurrrent chemotherapy, Docetaxel, Head and neck cancer, Radiotherapy",
author = "Kumiko Karasawa and H. Shinoda and Kuniaki Katsui and K. Seki and M. Kohno and N. Hanyu and S. Nasu and H. Muramatsu and K. Maebayashi and N. Mitsuhashi and T. Yoshihara",
year = "2002",
month = "11",
language = "English",
volume = "22",
pages = "3785--3788",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer

AU - Karasawa, Kumiko

AU - Shinoda, H.

AU - Katsui, Kuniaki

AU - Seki, K.

AU - Kohno, M.

AU - Hanyu, N.

AU - Nasu, S.

AU - Muramatsu, H.

AU - Maebayashi, K.

AU - Mitsuhashi, N.

AU - Yoshihara, T.

PY - 2002/11

Y1 - 2002/11

N2 - Background: This study was designed to evaluate the concomitant use of docetaxel and carboplatin for radiosensitization in head and neck cancer. Materials and Methods: One dose of docetaxel at 10 mg/m2 and five doses of carboplatin at AUC of 0.4 per week were administered to patients during the first two weeks of radiotherapy. Sixteen patients were treated with this regimen. Radiotherapy was given to a total dose of 64.8 to 82.0 Gy. Altered fractionation radiotherapy was performed in 12 patients with untreated advanced tumors. Results: The complete response (CR) rate was 81%, with a partial response (PR) rate of 19%. Toxicities included grade 3 mucositis in 69% of patients and grade 2 dermatitis in 56% of patients. Conclusion: This schedule of docetaxel and carboplatin combined with radiotherapy may become a useful approach for the management of head and neck cancer with proper management of mucositis.

AB - Background: This study was designed to evaluate the concomitant use of docetaxel and carboplatin for radiosensitization in head and neck cancer. Materials and Methods: One dose of docetaxel at 10 mg/m2 and five doses of carboplatin at AUC of 0.4 per week were administered to patients during the first two weeks of radiotherapy. Sixteen patients were treated with this regimen. Radiotherapy was given to a total dose of 64.8 to 82.0 Gy. Altered fractionation radiotherapy was performed in 12 patients with untreated advanced tumors. Results: The complete response (CR) rate was 81%, with a partial response (PR) rate of 19%. Toxicities included grade 3 mucositis in 69% of patients and grade 2 dermatitis in 56% of patients. Conclusion: This schedule of docetaxel and carboplatin combined with radiotherapy may become a useful approach for the management of head and neck cancer with proper management of mucositis.

KW - Chemoradiotherapy

KW - Concurrrent chemotherapy

KW - Docetaxel

KW - Head and neck cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036875536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036875536&partnerID=8YFLogxK

M3 - Article

C2 - 12552993

AN - SCOPUS:0036875536

VL - 22

SP - 3785

EP - 3788

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -